SCHEMBL30920826

SCHEMBL30920826

CC1(C(=O)NCc2cc3ccc(OCc4csnn4)cc3[nH]2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ METTL3 Q86U44 9/20 0.33
▸ METTL14 Q9HCE5 9/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ IKBKB O14920 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ MIF P14174 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ ACHE P22303 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30946137 0.86 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14ALDH1A1
SCHEMBL27247567 0.86 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14ALDH1A1
SCHEMBL27247773 0.85 L3MBTL1 (0.41) MTNR1AMTNR1BMETTL3METTL14ALDH1A1
SCHEMBL27246870 0.85 MTNR1A (0.38) MTNR1AMTNR1BMETTL3METTL14NPC1
SCHEMBL30920754 0.84 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14IKBKB
SCHEMBL30946157 0.84 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14FLT3
SCHEMBL30946257 0.83 MAPT (0.42) MTNR1AMTNR1BMETTL3METTL14ALDH1A1
SCHEMBL27247427 0.83 MIF (0.36) MTNR1AMTNR1BMETTL3METTL14IKBKB
SCHEMBL30920518 0.83 MTNR1A (0.37) MTNR1AMTNR1BMETTL3METTL14IKBKB
SCHEMBL30946202 0.83 HPGDS (0.38) MTNR1AMTNR1BMETTL3METTL14IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 MTNR1A 158/4885MTNR1B 111/4885METTL3 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback